|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-02
|
$144,556
|
$76,615
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
|
7R21CA175802-03
|
$171,825
|
$171,825
|
ROBEK, MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-02
|
|
$0
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
6R01CA174432-03
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-18
|
$294,353
|
$294,353
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
DNA Mismatch repair and cancer in murine models
|
6R01CA076329-19
|
$86,232
|
$86,232
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Core Support for Cancer Center
|
3P30CA013330-43S1
|
$199,871
|
$39,974
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Core Support for Cancer Center
|
5P30CA013330-42
|
|
$0
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Core Support for Cancer Center
|
6P30CA013330-43
|
$3,696,138
|
$739,228
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Treating pancreatic cancer with Listeria-32P
|
1R21CA199010-01
|
$16,676
|
$16,676
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Treating pancreatic cancer with Listeria-32P
|
6R21CA199010-02
|
$201,259
|
$201,259
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-04
|
|
$0
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
6R01CA170911-05
|
$346,525
|
$173,263
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
5R01CA161879-04
|
$326,465
|
$326,465
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
6R01CA161879-05
|
$1
|
$1
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
5R01CA160790-04
|
|
$0
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
6R01CA160790-05
|
$522,889
|
$522,889
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
6F31CA183493-02
|
$47,676
|
$23,838
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
5R01CA163907-04
|
|
$0
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
6R01CA163907-05
|
$346,525
|
$346,525
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
BASE PERIOD: STUDY INITIATION (09/30/2015 - 12/29/2015)
|
261201500022C
|
$137,084
|
$137,084
|
UNKNOWN, UNKNOWN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-02
|
$28,106
|
$14,053
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
The B7x pathway in the tumor microenvironment
|
6R01CA175495-03
|
$318,419
|
$159,210
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
The Impact of a Targeted CRC Screening Intervention among Latinos in Central PA
|
5K01CA151752-05
|
$137,943
|
$137,943
|
DOMINIC, ORALIA
|
ALLEGHENY-SINGER RESEARCH INSTITUTE
|
|
|
Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays
|
5R44CA161965-04
|
$499,744
|
$499,744
|
LIM, MARK
|
AMBERGEN, INC
|
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
5R01CA184820-02
|
$399,582
|
$399,582
|
DUBOIS, RAYMOND
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
1R01CA199948-01
|
$517,230
|
$517,230
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Multiplexed In Solution Protein Array (MISPA) for identifying novel protein inter
|
1R21CA196442-01
|
$235,226
|
$235,226
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Navigation from Community to Clinic to promote CRC Screening in Underserved Popul
|
5R01CA162393-04
|
$560,038
|
$560,038
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Modeling Neoplastic Progression in Barrett's Esophagus
|
7R01CA140657-07
|
$384,742
|
$384,742
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-02
|
$589,926
|
$589,926
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
1R01CA190776-01
|
$666,229
|
$666,229
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-13
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Advanced Glycation End-Products and Risk of Pancreatic Cancer
|
5R01CA172880-03
|
$498,656
|
$498,656
|
JIAO, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Novel targets that are deregulated by loss of PTEN
|
5R01CA108614-09
|
$293,578
|
$293,578
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$536,378
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$19,066
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$31,118
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Targeting Stat1 and Stat3 to Reverse Radioresistance in Head and Neck Cancer
|
1R21CA191556-01
|
$206,081
|
$206,081
|
TWEARDY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
|
5U01CA170930-03
|
$584,586
|
$584,586
|
VERSALOVIC, JAMES
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
1R01CA183984-01A1
|
$472,669
|
$472,669
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
1R01CA184792-01A1
|
$360,402
|
$360,402
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Familial and Early Onset Colorectal Cancer
|
2R01CA072851-19
|
$372,400
|
$372,400
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-02
|
$320,751
|
$320,751
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data
|
5U01CA187956-02
|
$571,122
|
$571,122
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
CpG-ODN Coated Hollow Gold Nanoshells for Photothermal Therapy
|
5R01CA172836-03
|
$342,894
|
$171,447
|
FOSTER, AARON
|
BELLICUM PHARMACEUTICALS, INC.
|
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
1U01CA199252-01
|
$1,080,326
|
$540,163
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-02
|
$359,556
|
$359,556
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Controlling cancer with aspirin-triggered stimulation of resolution
|
5R01CA170549-04
|
$506,329
|
$172,152
|
PANIGRAHY, DIPAK
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting orphan nuclear receptor TR3/Nur77 for tumor angiogenesis
|
1R03CA191463-01A1
|
$87,000
|
$87,000
|
ZENG, HUIYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Total relevant funding to Digestive Diseases for this search: $470,961,767
|
